Terminated
A Study of K-645 in the Treatment of Multiple Migraine Attacks
NCT07116499· Phase 2· TriGemX Bio, Inc.· Source
Completed
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
NCT06848075· Phase 2· TriGemX Bio, Inc.· Source
Completed
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
NCT06717425· Phase 2· Pfizer· Source
Completed
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06683508· Phase 2· Eli Lilly and Company· Source
Completed
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
NCT06603623· Phase 2· Biohaven Therapeutics Ltd.· Source
Completed
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
NCT06584916· Phase 3· Eli Lilly and Company· Source
Completed
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
NCT06229145· Phase 4· Amgen· Source
Completed
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
NCT06326060· Phase 2· Novo Nordisk A/S· Source
Completed
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
NCT06299098· Phase 2· Regeneron Pharmaceuticals· Source
Completed
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06230523· Phase 2· Eli Lilly and Company· Source
Completed
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528· Phase 3· Boehringer Ingelheim· Source
Completed
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT06066515· Phase 3· Boehringer Ingelheim· Source
Completed
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06124807· Phase 2· Eli Lilly and Company· Source
Completed
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06047548· Phase 3· Eli Lilly and Company· Source
Completed
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
NCT06019559· Phase 2· TriGemX Bio, Inc.· Source
Completed
Safety and Efficacy Study of S-309309 in Obese Adults
NCT05925114· Phase 2· Shionogi· Source
Completed
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
NCT05822830· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421· Phase 3· Eli Lilly and Company· Source
Completed
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
NCT05394519· Phase 3· Novo Nordisk A/S· Source
Completed
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
NCT05586958· Phase 3· LG Chem· Source
Completed
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
NCT05514535· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
NCT05259033· Phase 3· Novo Nordisk A/S· Source
Completed
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
NCT05275400· Phase 3· Eli Lilly and Company· Source
Terminated
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
NCT04804033· Phase 2/3· Pfizer· Source
Completed
The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity
NCT04222322· Epitomee medical· Source
Completed
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
NCT04184622· Phase 3· Eli Lilly and Company· Source
Completed
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
NCT03914326· Phase 3· Novo Nordisk A/S· Source